---
document_datetime: 2025-12-25 12:44:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/shingrix.html
document_name: shingrix.html
version: success
processing_time: 0.1156631
conversion_datetime: 2025-12-28 19:12:56.187677
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Shingrix

[RSS](/en/individual-human-medicine.xml/65658)

##### Authorised

This medicine is authorised for use in the European Union

herpes zoster vaccine (recombinant, adjuvanted) Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Shingrix](#news-on)
- [More information on Shingrix](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Shingrix is a vaccine used in adults aged 50 years and over to protect against shingles (herpes zoster) and post-herpetic neuralgia (long-lasting nerve pain following shingles). It can also be used from the age of 18 years and over in adults who are at increased risk of herpes zoster.

Shingles is a painful, blistering rash caused by the reactivation of the virus that causes chickenpox. After a patient has had chickenpox, the virus can lie dormant in the nerves and become active again if the immune system (the body's natural defences) weakens due, for example, to ageing or to an illness.

Shingrix contains a protein (glycoprotein E) from varicella zoster virus, the virus that causes chickenpox.

Expand section

Collapse section

## How is Shingrix used?

Shingrix can only be obtained with a prescription and should be used according to official recommendations. It is available as a powder and a suspension to be mixed together by a doctor or a nurse before being injected into the upper arm muscle.

The vaccination course consists of 2 injections given 2 months apart. If necessary, the second dose can be given later but within 6 months after the first dose. People whose immune system does not work properly and who would benefit from a shorter vaccination schedule can have the second dose one to two months after the first dose.

For more information about using Shingrix, see the package leaflet or contact your doctor or pharmacist.

## How does Shingrix work?

Shingrix has been designed to prevent shingles in people who have been in contact with the varicella zoster virus and have already developed antibodies against the virus.

Shingrix contains small amounts of a surface antigen (protein from the surface) of the virus to stimulate the body to make antibodies against the virus. It also contains an 'adjuvant' which is made of substances to help strengthen the immune responses to the vaccine.

Patients given Shingrix will be able to produce antibodies against the virus more quickly when the virus is reactivated and they will therefore have protection against the disease.

## What benefits of Shingrix have been shown in studies?

Shingrix has been shown in two main studies to be effective at preventing shingles and post-herpetic neuralgia in patients 50 years and older.

In the first study, 7,695 received Shingrix and 7,710 received placebo (a dummy treatment). After just over 3 years on average, 6 adults had had shingles in the Shingrix group compared with 210 in the placebo group. After almost 4 years, nobody had had post-herpetic neuralgia in the Shingrix group compared with 18 in the placebo group. This indicates that Shingrix prevented 97% of shingles cases and 100% of cases of post-herpetic neuralgia in this study.

The second study involved adults aged 70 and over who received either Shingrix or placebo. Looking at the results for adults in this age group from both studies together, 25 adults out of 8,250 who received Shingrix had shingles within 4 years after vaccination compared with 284 out of 8,346 who received placebo. After 4 years, 4 adults had had post-herpetic neuralgia in the Shingrix group compared with 36 in the placebo group. This indicates that Shingrix prevented 91% of shingles cases and 89% of cases of post-herpetic neuralgia in adults aged 70 years and older.

Shingrix was also effective in two studies in adults aged 18 years and above at increased risk of developing herpes zoster. In the first study, involving people who had received an autologous (from the patient's own body) stem cell transplant, the number of people who had herpes zoster was 49 (out of 870) in the Shingrix group compared with 135 (out of 851) in the placebo group; in the second study, involving patients with blood cancer, these figures were 2 (out of 259 people) and 14 (out of 256), respectively. These studies indicate that Shingrix prevented 68% and 87% of cases, respectively.

## What are the risks associated with Shingrix?

The most common side effects with Shingrix (which may affect more than 1 in 10 people) are reactions at the site of injection (such as pain, redness and swelling), chills, fever, muscle pain, tiredness, headache and side effects of the digestive system such as nausea, vomiting, diarrhoea and stomach pain. Most of these reactions last for 2 to 3 days.

For the full list of side effects and restrictions with Shingrix, see the package leaflet.

## Why is Shingrix authorised in the EU?

Shingrix has been shown to be highly effective at preventing shingles and post-herpetic neuralgia in adults older than 50 years for at least 4 years after vaccination. The vaccine is also effective at protecting adults older than 18 years who are at increased risk of herpes zoster. Side effects related to the use of Shingrix seemed to be mostly temporary and were manageable with standard care.

The European Medicines Agency therefore decided that Shingrix's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Shingrix?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Shingrix have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Shingrix is continuously monitored. Side effects reported with Shingrix are carefully evaluated and any necessary action taken to protect patients.

## Other information about Shingrix

Shingrix received a marketing authorisation valid throughout the EU on 21 March 2018.

Shingrix : EPAR - Medicine overview

Reference Number: EMA/422738/2020

English (EN) (116.03 KB - PDF)

**First published:** 28/03/2018

**Last updated:** 28/09/2020

[View](/en/documents/overview/shingrix-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-701)

български (BG) (139.86 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/bg/documents/overview/shingrix-epar-medicine-overview_bg.pdf)

español (ES) (116.02 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/es/documents/overview/shingrix-epar-medicine-overview_es.pdf)

čeština (CS) (138.71 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/cs/documents/overview/shingrix-epar-medicine-overview_cs.pdf)

dansk (DA) (114.85 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/da/documents/overview/shingrix-epar-medicine-overview_da.pdf)

Deutsch (DE) (119.49 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/de/documents/overview/shingrix-epar-medicine-overview_de.pdf)

eesti keel (ET) (112.23 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/et/documents/overview/shingrix-epar-medicine-overview_et.pdf)

ελληνικά (EL) (137.45 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/el/documents/overview/shingrix-epar-medicine-overview_el.pdf)

français (FR) (116.18 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/fr/documents/overview/shingrix-epar-medicine-overview_fr.pdf)

hrvatski (HR) (139.92 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/hr/documents/overview/shingrix-epar-medicine-overview_hr.pdf)

italiano (IT) (115.62 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/it/documents/overview/shingrix-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (155.49 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/lv/documents/overview/shingrix-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (138.39 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/lt/documents/overview/shingrix-epar-medicine-overview_lt.pdf)

magyar (HU) (139.48 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/hu/documents/overview/shingrix-epar-medicine-overview_hu.pdf)

Malti (MT) (147.6 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/mt/documents/overview/shingrix-epar-medicine-overview_mt.pdf)

Nederlands (NL) (115.07 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/nl/documents/overview/shingrix-epar-medicine-overview_nl.pdf)

polski (PL) (141.05 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/pl/documents/overview/shingrix-epar-medicine-overview_pl.pdf)

português (PT) (116.32 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/pt/documents/overview/shingrix-epar-medicine-overview_pt.pdf)

română (RO) (137.35 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/ro/documents/overview/shingrix-epar-medicine-overview_ro.pdf)

slovenčina (SK) (139.1 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/sk/documents/overview/shingrix-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.06 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/sl/documents/overview/shingrix-epar-medicine-overview_sl.pdf)

Suomi (FI) (114.2 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/fi/documents/overview/shingrix-epar-medicine-overview_fi.pdf)

svenska (SV) (114.93 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

28/09/2020

[View](/sv/documents/overview/shingrix-epar-medicine-overview_sv.pdf)

Shingrix : EPAR - Risk management plan

English (EN) (6.37 MB - PDF)

**First published:** 28/09/2020

**Last updated:** 19/12/2025

[View](/en/documents/rmp/shingrix-epar-risk-management-plan_en.pdf)

## Product information

Shingrix : EPAR - Product Information

English (EN) (953.36 KB - PDF)

**First published:** 28/03/2018

**Last updated:** 19/12/2025

[View](/en/documents/product-information/shingrix-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-61)

български (BG) (1.3 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/bg/documents/product-information/shingrix-epar-product-information_bg.pdf)

español (ES) (1.03 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/11/2025

[View](/es/documents/product-information/shingrix-epar-product-information_es.pdf)

čeština (CS) (1.16 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/cs/documents/product-information/shingrix-epar-product-information_cs.pdf)

dansk (DA) (1.05 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/da/documents/product-information/shingrix-epar-product-information_da.pdf)

Deutsch (DE) (1.13 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/de/documents/product-information/shingrix-epar-product-information_de.pdf)

eesti keel (ET) (1021.17 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/et/documents/product-information/shingrix-epar-product-information_et.pdf)

ελληνικά (EL) (1.19 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/el/documents/product-information/shingrix-epar-product-information_el.pdf)

français (FR) (1.04 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/fr/documents/product-information/shingrix-epar-product-information_fr.pdf)

hrvatski (HR) (1.06 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/hr/documents/product-information/shingrix-epar-product-information_hr.pdf)

íslenska (IS) (1.09 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/is/documents/product-information/shingrix-epar-product-information_is.pdf)

italiano (IT) (1.04 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/it/documents/product-information/shingrix-epar-product-information_it.pdf)

latviešu valoda (LV) (1.1 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/lv/documents/product-information/shingrix-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.11 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/lt/documents/product-information/shingrix-epar-product-information_lt.pdf)

magyar (HU) (1.12 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/hu/documents/product-information/shingrix-epar-product-information_hu.pdf)

Malti (MT) (1.28 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/mt/documents/product-information/shingrix-epar-product-information_mt.pdf)

Nederlands (NL) (1.05 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/nl/documents/product-information/shingrix-epar-product-information_nl.pdf)

norsk (NO) (1011.22 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/no/documents/product-information/shingrix-epar-product-information_no.pdf)

polski (PL) (1021.63 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/pl/documents/product-information/shingrix-epar-product-information_pl.pdf)

português (PT) (1.06 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/pt/documents/product-information/shingrix-epar-product-information_pt.pdf)

română (RO) (1.08 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/ro/documents/product-information/shingrix-epar-product-information_ro.pdf)

slovenčina (SK) (1.11 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/sk/documents/product-information/shingrix-epar-product-information_sk.pdf)

slovenščina (SL) (1.08 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/sl/documents/product-information/shingrix-epar-product-information_sl.pdf)

Suomi (FI) (1.02 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/fi/documents/product-information/shingrix-epar-product-information_fi.pdf)

svenska (SV) (1.04 MB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/sv/documents/product-information/shingrix-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** X/0000243671 18/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Shingrix : EPAR - All Authorised presentations

English (EN) (80.18 KB - PDF)

**First published:** 28/03/2018

**Last updated:** 19/12/2025

[View](/en/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-536)

български (BG) (98.58 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/bg/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_bg.pdf)

español (ES) (85.24 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/es/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_es.pdf)

čeština (CS) (131.21 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/cs/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (89.85 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/da/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (81.64 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/de/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (79.55 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/et/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (105.14 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/el/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_el.pdf)

français (FR) (80.05 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/fr/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (103.49 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/hr/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (79.87 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/is/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_is.pdf)

italiano (IT) (81.02 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/it/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (101.92 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/lv/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (106.87 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/lt/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (102.33 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/hu/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (107.1 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/mt/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (79.99 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/nl/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (81.6 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/no/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_no.pdf)

polski (PL) (86.06 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/pl/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_pl.pdf)

português (PT) (81.09 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/pt/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_pt.pdf)

română (RO) (103.17 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/ro/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (73.7 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/sk/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (79.33 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/sl/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (80.32 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/fi/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (60.28 KB - PDF)

**First published:**

28/03/2018

**Last updated:**

19/12/2025

[View](/sv/documents/all-authorised-presentations/shingrix-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Shingrix Active substance recombinant varicella zoster virus glycoprotein E International non-proprietary name (INN) or common name herpes zoster vaccine (recombinant, adjuvanted) Therapeutic area (MeSH) Herpes Zoster Anatomical therapeutic chemical (ATC) code J07BK03

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:

- adults 50 years of age or older;
- adults 18 years of age or older at increased risk of HZ.

The use of Shingrix should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/004336 Marketing authorisation holder

GlaxoSmithKline Biologicals S.A.

Rue de l'Institut, 89

Marketing authorisation issued 21/03/2018 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Shingrix : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (173.5 KB - PDF)

**First published:** 17/07/2025

**Last updated:** 19/12/2025

[View](/en/documents/procedural-steps-after/shingrix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Shingrix : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (293.32 KB - PDF)

**First published:** 22/08/2019

**Last updated:** 17/07/2025

[View](/en/documents/procedural-steps-after/shingrix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Shingrix-X-0000243671 : EPAR - Assessment report - Extension

Adopted

Reference Number: EMADOC-1700519818-2471078

English (EN) (570.04 KB - PDF)

**First published:** 19/12/2025

[View](/en/documents/variation-report/shingrix-x-0000243671-epar-assessment-report-extension_en.pdf)

Shingrix-H-C-4336-II-0022 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/447929/2020

English (EN) (7.65 MB - PDF)

**First published:** 28/09/2020

[View](/en/documents/variation-report/shingrix-h-c-4336-ii-0022-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Shingrix (II-22)

Adopted

Reference Number: EMA/CHMP/383838/2020

English (EN) (136.82 KB - PDF)

**First published:** 24/07/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-shingrix-ii-22_en.pdf)

## Initial marketing authorisation documents

Shingrix : EPAR - Public assessment report

Adopted

Reference Number: EMA/88588/2018

English (EN) (3.69 MB - PDF)

**First published:** 28/03/2018

**Last updated:** 28/03/2018

[View](/en/documents/assessment-report/shingrix-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Shingrix

Adopted

Reference Number: EMA/CHMP/811150/2017

English (EN) (69.26 KB - PDF)

**First published:** 26/01/2018

**Last updated:** 26/01/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-shingrix_en.pdf)

#### News on Shingrix

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020) 24/07/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2018) 26/01/2018

#### More information on Shingrix

- [EMEA-001426-PIP01-13-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001426-pip01-13-m03)
- [A retrospective matched cohort study on the association between herpes zoster vaccination and dementia and mild cognitive impairment using electronic health records (ZOSTER-122 AIML 222419) - post-authorisation study](https://catalogues.ema.europa.eu/study/108337)
- [213825-Non-interventional (observational) post-licensure study to assess the vaccine effectiveness and safety of recombinant zoster vaccine (RZV) in the rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) patient populations in adults 18 years of age and older (EPI-ZOSTER-044 VE US) - post-authorisation study](https://catalogues.ema.europa.eu/study/48446)
- [209696 - A targeted safety study, EPI-ZOSTER-032 VS US DB, to evaluate the safety of Shingrix in adults ≥ 65 years of age in the United States. - post-authorisation study](https://catalogues.ema.europa.eu/study/48959)
- [209452 - A targeted safety study, EPI-ZOSTER-030 VS US DB, to evaluate the safety of Shingrix in adults ≥ 50 years of age in the United States - post-authorisation study](https://catalogues.ema.europa.eu/study/50411)
- [Safety and effectiveness of RZV in adults ≥18 years of age with Systemic lupus erythematosus (SLE) or Multiple sclerosis (MS) (EPI-ZOSTER-041 VS US DB 215104) - post-authorisation study](https://catalogues.ema.europa.eu/study/108331)
- [Postmarketing commitment safety study of HZ/su to evaluate pregnancy exposures and outcomes in immunodeficient or immunosuppressed women between 18 and 49 years of age (EPI-ZOSTER-039 VS US DB 214420) - post-authorisation study](https://catalogues.ema.europa.eu/study/105603)
- [209570 - Long-Term Effectiveness Study of Shingrix in Adults ≥ 50 Years of Age in the US (EPI-ZOSTER-031 VE US) - post-authorisation study](https://catalogues.ema.europa.eu/study/46860)
- [219111- A retrospective matched cohort database study in the United States to evaluate the effectiveness of recombinant zoster vaccine (RZV) in patients with autoimmune diseases (AIDs) (EPI-ZOSTER-097 VE US DB) - post-authorisation study](https://catalogues.ema.europa.eu/study/49979)
- [Non-interventional (observational) post-licensure study to assess the effectiveness and safety of recombinant zoster vaccine in adults aged =18 years with psoriasis or psoriatic arthritis (EPI-ZOSTER-045 VE US 216976) - post-authorisation study](https://catalogues.ema.europa.eu/study/108334)
- [212853 - Shingrix for intramuscular injection Drug Use Investigation - post-authorisation study](https://catalogues.ema.europa.eu/study/46663)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)
- [Vaccines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A76)

**This page was last updated on** 19/12/2025

## Share this page

[Back to top](#main-content)